Tagged with BioTech

Austria Michael Krebs, managing director of the Institute of Molecular Biotechnology (IMBA), the leading publicly funded non-university biomedical research organization in Austria, provides an overview of IMBA’s role in the Austrian biomedical ecosystem. Furthermore, he gives an insight into Austria compared to the rest of Europe and delivers exciting news on…

Austria Philipp von Lattorff, country managing director of Boehringer Ingelheim’s Regional Centre Vienna (RCV) discusses the current mandate of the center and the dynamic performance of its 33 members, as well as providing an overview of the soon to be completed 700 million EUR biopharmaceutical production plant to be built in…

Colombia Oscar Fernando Otalora Gomez, Executive Director of HB Human Bioscience, discusses the importance of bringing innovation and technology to the Colombian market, while being committed to providing medication at a reasonable price to save lives. To begin with, could you introduce HB Human Bioscience to our international audience and give…

Austria Sylvia Hofinger, director general of the Association of the chemical industry of Austria (FCIO), the representing voice of the Austrian chemical industry, discusses the drug pricing regulations that are affecting patients´ access to innovative medicines that in turn is harming the nation´s chances of potential investments in the pharmaceutical sector,…

Indonesia Evie Yulin, biopharma country director at Merck Indonesia, speaks towards the meaning of innovation in emerging countries and how the company engages in innovation beyond products. Since 2012, Merck has been implementing “Fit for 2018” – a transformation program aiming to drive the growth of the company globally. How has this…

Colombia Sandra Cifuentes, General Manager of Astellas Farma Colombia, one of the most recent entrants in the Colombian market, explains the strategic priorities for establishing a strong position in the country, where the prime focus is on bringing a collaborative approach that can unite the industry towards a more sustainable healthcare…

Hong Kong In 2017, Hong Kong fended off perennial competitors, life sciences hubs and innovation powerhouses, Switzerland and Singapore, to rank first in the International Institute for Management Development (IMD)’s World Competitiveness Rankings, clear evidence that conditions are ripe in Hong Kong to develop the first biotech unicorn – a start-up company…

Hong Kong Described as the first unicorn [a startup company valued at over USD 1 billion] of Hong Kong, Cirina has recently merged with Grail to further improve detection of cancer at its early stage. Pharmaboardroom sat down with Professor Denis Lo, the man behind Cirina’s technology, to further discuss his groundbreaking…

Hong Kong Professor Cheng, managing director of the Hong Kong Institute of Biotechnology, introduces the organization’s mission to improve development of biotechnology and traditional Chinese medicine sectors as well as the main challenges ahead. What is the mandate of the Hong Kong Institute of Biotechnology (HKIB)? “Our mission statement was – and…

Hong Kong Alexandre de Muralt, the man behind Merck’s operations in Hong Kong and Taiwan discusses the nuances of these two local markets. In addition, he shares his insights on how Merck’s transformation has impacted local affiliates. Can you begin by telling us about Merck’s strategic transformation in recent years? “Founded in…

Japan Kenichi Tamiya, director for Biomedical Policy at the Kobe City Government and managing director of the Kobe Foundation for Biomedical Research and Innovation (FBRI), discusses the central Japanese city of Kobe’s significant potential as a cutting-edge R&D hub for both the national and global life science industries. “Alongside promoting translational…

Japan Prof. Yoshiaki Tsukamoto, executive director of the Japan Bioindustry Association (JBA), talked exclusively to PharmaBoardroom at the BIO 2017 conference in San Diego on the role of his organization within Japan and his mission to instill a start-up culture within the Japanese biopharmaceutical industry. “[My mission is] urging universities, biotech start-ups…